

Research use only. Not for use in diagnostic procedures.

LANCE[®] Ultra

Eu-W1024 labeled Anti-phospho-Histone H3 (Ser10) Antibody

Product number:	TRF0210-D	I	ot Number:	3208821	
Product Format:	TRF0210-D: 10 μg TRF0210-M: 100 μg				$\overline{}$
Manufacturing date:	February 7, 2023	Document version:	1		
Product Information					
Antibody:	Europium-labeled mouse monoclonal antibody recognizing phospho-Ser10 in human Histone H3.				
Storage Buffer:	50 mM Tris-HCl (pH 7.4), 0.9% NaCl, 0.1% BSA and 0.05% sodium azide as preservative				
Molecular Weight:	160 000				
Stability:	This product is stable for at least 12 months from the manufacturing date when stored in its original packaging and at the recommended storage conditions.				
Storage Conditions:	Store at 4°C				

Quality Control

The QC release specifications are based on spectrophotometric analysis of the labeled antibody. We certify that results meet our quality release criteria.

Labeling Ratio:	7.75
Concentration:	100 μg/mL (0.625 μM)

Recommended Assay Conditions

SUGGESTED METHOD:

(Specific applications might require optimization)

Reagent Preparation


- Prepare 1X Kinase Assay Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 10 mM MgCl₂, 2 mM DTT and 0.01% Tween-20.
- Prepare a 2X Aurora B solution: dilute enzyme to a concentration of 0.2 nM in 1X Kinase Assay Buffer. Keep on ice.
- Prepare a 4X ULight-Histone H3 (Thr3/Ser10) Peptide solution: dilute ULight-Histone H3 (Thr3/Ser10) Peptide to a concentration of 200 nM in 1X Kinase Assay Buffer.
- Prepare a 4X ATP solution: dilute ATP to concentrations ranging from 40 nM to 4 mM (serial half-log dilutions) in 1X Kinase Assay Buffer. Keep on ice.
- Prepare 1X Detection Buffer: dilute 0.5 mL of 10X Detection Buffer with 4.5 mL of H₂O.
- Prepare a 4X Stop solution*: dilute EDTA to a concentration of 24 mM in 1X Detection Buffer.
- Prepare a 4X Detection Mix: dilute Europium-anti-phospho-DNA Topoisomerase 2-alpha (Thr1342) Antibody to a concentration of 8 nM in 1X Detection Buffer.


Protocol

- Pipet 5 µL of 2X Aurora B solution into a 384-well white OptiPlate-384 (0.1 nM final concentration).
- Add 2.5 μL of 4X ULight-Histone H3 (Thr3/Ser10) Peptide solution (50 nM final concentration).
- Add 2.5 µL of 4X ATP solution (10 nM to 1 mM final concentrations).
- Cover plate with TopSeal-A and incubate 60 min at 23°C.
- Add 5 µL of 4X Stop solution* and incubate 5 min at 23°C.
- Add 5 µL of Detection Mix (2 nM Europium-anti-phospho-Histone H3 (Ser10) Antibody final concentration).
- Cover plate with TopSeal-A and incubate 60 min at 23°C.
- Remove TopSeal-A and read in TR-FRET mode at 665 nm (excitation at 320 or 340 nm).

*Alternatively, the Stop solution and Detection Mix can be premixed and added together to the kinase reaction.

Typical Product Data





Suggested Materials

Supplier

- Substrate: ULight[™]- Histone H3 (Thr3/Ser10) Peptide Revvity Inc
- Antibody: Eu- anti-phospho-Histone H3 (Ser10) Antibody
- Kinase: Aurora B
- Detection Buffer: LANCE[®] Detection Buffer, 10X
- Plate: OptiPlate[™]-384, white
- TopSeal[™]-A

Inc Revvity Inc Carna Biosciences Revvity Inc Revvity Inc Revvity Inc

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

TRF0210-R Rev01



Revvity, Inc. 940 Winter Street Waltham, MA 02451 USA (800) 762-4000 www.revvity.com

For a complete listing of our global offices, visit <u>www.revvity.com</u> Copyright ©2023, Revvity, Inc. All rights reserved.